FBS and Therapeutic Safety: Minimizing Immune Risks Immunogenicity—the risk of triggering immune responses—is a critical concern when using Fetal Bovine Serum (FBS) in therapeutic cell cultures. Even trace bovine proteins can cause patient rejection, limiting FBS use in drug production. By 2026, innovations reducing FBS immunogenicity are making it safer for applications like...